207 related articles for article (PubMed ID: 29740204)
1. Oral treatment with plecanatide or dolcanatide attenuates visceral hypersensitivity
Boulete IM; Thadi A; Beaufrand C; Patwa V; Joshi A; Foss JA; Eddy EP; Eutamene H; Palejwala VA; Theodorou V; Shailubhai K
World J Gastroenterol; 2018 May; 24(17):1888-1900. PubMed ID: 29740204
[TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal pain: unraveling a novel endogenous pathway through uroguanylin/guanylate cyclase-C/cGMP activation.
Silos-Santiago I; Hannig G; Eutamene H; Ustinova EE; Bernier SG; Ge P; Graul C; Jacobson S; Jin H; Liong E; Kessler MM; Reza T; Rivers S; Shea C; Tchernychev B; Bryant AP; Kurtz CB; Bueno L; Pezzone MA; Currie MG
Pain; 2013 Sep; 154(9):1820-1830. PubMed ID: 23748116
[TBL] [Abstract][Full Text] [Related]
3. Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis.
Shailubhai K; Palejwala V; Arjunan KP; Saykhedkar S; Nefsky B; Foss JA; Comiskey S; Jacob GS; Plevy SE
World J Gastrointest Pharmacol Ther; 2015 Nov; 6(4):213-22. PubMed ID: 26558155
[TBL] [Abstract][Full Text] [Related]
4. Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate.
Castro J; Harrington AM; Hughes PA; Martin CM; Ge P; Shea CM; Jin H; Jacobson S; Hannig G; Mann E; Cohen MB; MacDougall JE; Lavins BJ; Kurtz CB; Silos-Santiago I; Johnston JM; Currie MG; Blackshaw LA; Brierley SM
Gastroenterology; 2013 Dec; 145(6):1334-46.e1-11. PubMed ID: 23958540
[TBL] [Abstract][Full Text] [Related]
5. Multispecies probiotic protects gut barrier function in experimental models.
Nébot-Vivinus M; Harkat C; Bzioueche H; Cartier C; Plichon-Dainese R; Moussa L; Eutamene H; Pishvaie D; Holowacz S; Seyrig C; Piche T; Theodorou V
World J Gastroenterol; 2014 Jun; 20(22):6832-43. PubMed ID: 24944474
[TBL] [Abstract][Full Text] [Related]
6. Chitin-glucan improves important pathophysiological features of irritable bowel syndrome.
Valibouze C; Dubuquoy C; Chavatte P; Genin M; Maquet V; Modica S; Desreumaux P; Rousseaux C
World J Gastroenterol; 2024 Apr; 30(16):2258-2271. PubMed ID: 38690023
[TBL] [Abstract][Full Text] [Related]
7. Peripheral Guanylate Cyclase-C modulation of corticolimbic activation and corticotropin-releasing factor signaling in a rat model of stress-induced colonic hypersensitivity.
Ligon CO; Hannig G; Greenwood-Van Meerveld B
Neurogastroenterol Motil; 2021 Mar; 33(3):e14076. PubMed ID: 33373484
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis.
Shah ED; Kim HM; Schoenfeld P
Am J Gastroenterol; 2018 Mar; 113(3):329-338. PubMed ID: 29380823
[TBL] [Abstract][Full Text] [Related]
9. Plecanatide for the treatment of chronic idiopathic constipation in adult patients.
Bassotti G; Usai Satta P; Bellini M
Expert Rev Clin Pharmacol; 2019 Nov; 12(11):1019-1026. PubMed ID: 31575291
[No Abstract] [Full Text] [Related]
10. Efficacy and safety of plecanatide in treating constipation predominant irritable bowel syndrome.
Miner PB
Expert Opin Pharmacother; 2018 Feb; 19(2):177-183. PubMed ID: 29376436
[TBL] [Abstract][Full Text] [Related]
11. Plecanatide for the treatment of constipation-predominant irritable bowel syndrome.
Miner PB
Expert Rev Gastroenterol Hepatol; 2020 Feb; 14(2):71-84. PubMed ID: 31985305
[No Abstract] [Full Text] [Related]
12. Mast cell tryptase reduces junctional adhesion molecule-A (JAM-A) expression in intestinal epithelial cells: implications for the mechanisms of barrier dysfunction in irritable bowel syndrome.
Wilcz-Villega EM; McClean S; O'Sullivan MA
Am J Gastroenterol; 2013 Jul; 108(7):1140-51. PubMed ID: 23588236
[TBL] [Abstract][Full Text] [Related]
13. Antinociceptive effect of VSL#3 on visceral hypersensitivity in a rat model of irritable bowel syndrome: a possible action through nitric oxide pathway and enhance barrier function.
Dai C; Guandalini S; Zhao DH; Jiang M
Mol Cell Biochem; 2012 Mar; 362(1-2):43-53. PubMed ID: 22020749
[TBL] [Abstract][Full Text] [Related]
14. Melittin as an epithelial permeability enhancer I: investigation of its mechanism of action in Caco-2 monolayers.
Maher S; Feighery L; Brayden DJ; McClean S
Pharm Res; 2007 Jul; 24(7):1336-45. PubMed ID: 17373574
[TBL] [Abstract][Full Text] [Related]
15. Chronic stress and intestinal permeability: Lubiprostone regulates glucocorticoid receptor-mediated changes in colon epithelial tight junction proteins, barrier function, and visceral pain in the rodent and human.
Zong Y; Zhu S; Zhang S; Zheng G; Wiley JW; Hong S
Neurogastroenterol Motil; 2019 Feb; 31(2):e13477. PubMed ID: 30284340
[TBL] [Abstract][Full Text] [Related]
16. Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain.
Eutamene H; Bradesi S; Larauche M; Theodorou V; Beaufrand C; Ohning G; Fioramonti J; Cohen M; Bryant AP; Kurtz C; Currie MG; Mayer EA; Bueno L
Neurogastroenterol Motil; 2010 Mar; 22(3):312-e84. PubMed ID: 19706070
[TBL] [Abstract][Full Text] [Related]
17. Glutamine and arginine improve permeability and tight junction protein expression in methotrexate-treated Caco-2 cells.
Beutheu S; Ghouzali I; Galas L; Déchelotte P; Coëffier M
Clin Nutr; 2013 Oct; 32(5):863-9. PubMed ID: 23428392
[TBL] [Abstract][Full Text] [Related]
18. Emerging treatments in Neurogastroenterology: Perspectives of guanylyl cyclase C agonists use in functional gastrointestinal disorders and inflammatory bowel diseases.
Jarmuż A; Zielińska M; Storr M; Fichna J
Neurogastroenterol Motil; 2015 Aug; 27(8):1057-68. PubMed ID: 25930667
[TBL] [Abstract][Full Text] [Related]
19. Linaclotide activates guanylate cyclase-C/cGMP/protein kinase-II-dependent trafficking of CFTR in the intestine.
Ahsan MK; Tchernychev B; Kessler MM; Solinga RM; Arthur D; Linde CI; Silos-Santiago I; Hannig G; Ameen NA
Physiol Rep; 2017 Jun; 5(11):. PubMed ID: 28592587
[TBL] [Abstract][Full Text] [Related]
20. Methotrexate modulates tight junctions through NF-κB, MEK, and JNK pathways.
Beutheu Youmba S; Belmonte L; Galas L; Boukhettala N; Bôle-Feysot C; Déchelotte P; Coëffier M
J Pediatr Gastroenterol Nutr; 2012 Apr; 54(4):463-70. PubMed ID: 22197938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
